Alnylam Pharmaceuticals Inc
(NAS:ALNY)
$
265.855
-3.095 (-1.15%)
Market Cap: 34.29 Bil
Enterprise Value: 33.21 Bil
PE Ratio: 0
PB Ratio: 1,063.42
GF Score: 78/100 Alnylam Pharmaceuticals Inc at Bank of America Global Research Healthcare Conference (Virtual) Transcript
May 11, 2021 / 06:45PM GMT
Release Date Price:
$132.41
(+2.94%)
Tazeen Ahmad
BofA Securities, Research Division - VP
Good afternoon, everyone. Thanks for joining us at our Bank of America Healthcare Conference, usually held in Vegas. Of course, this year is virtual. We hope to go back to Vegas sometime soon. It's our pleasure to be hosting our next presenting company, Alnylam. Presenting for Alnylam is none other than John Maraganore.
John, you don't need an introduction. So I think we should probably just go straight into Q&A.
John M. Maraganore
Alnylam Pharmaceuticals, Inc. - CEO & Executive Director
Sure.
Questions & Answers
Tazeen Ahmad;John M. Maraganore
BofA Securities, Research Division - VP;
For those who might not be as familiar with Alnylam, maybe we can do with super quick overview in 2 minutes, which I know is a challenge because you've got a lot going on. But hopefully, we'll be able to get into a little bit more detail on some of the key items over the course of the next 30 minutes, if that's okay.
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot